SVB Wealth LLC Buys 146 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

SVB Wealth LLC grew its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,983 shares of the company’s stock after buying an additional 146 shares during the period. SVB Wealth LLC’s holdings in IDEXX Laboratories were worth $1,101,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. OFI Invest Asset Management bought a new position in IDEXX Laboratories in the third quarter valued at $25,000. Valley National Advisers Inc. increased its position in shares of IDEXX Laboratories by 84.6% during the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after purchasing an additional 22 shares during the last quarter. Altshuler Shaham Ltd purchased a new position in shares of IDEXX Laboratories during the 4th quarter valued at about $26,000. Geo Capital Gestora de Recursos Ltd purchased a new position in shares of IDEXX Laboratories during the 3rd quarter valued at about $28,000. Finally, Covestor Ltd lifted its position in IDEXX Laboratories by 71.8% in the 3rd quarter. Covestor Ltd now owns 67 shares of the company’s stock worth $29,000 after buying an additional 28 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Jonathan Jay Mazelsky sold 12,000 shares of IDEXX Laboratories stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the sale, the chief executive officer now owns 79,247 shares of the company’s stock, valued at approximately $45,377,624.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total value of $6,871,320.00. Following the completion of the transaction, the chief executive officer now owns 79,247 shares of the company’s stock, valued at approximately $45,377,624.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Brian P. Mckeon sold 23,326 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total value of $13,296,053.26. Following the sale, the chief financial officer now owns 29,718 shares in the company, valued at $16,939,557.18. The disclosure for this sale can be found here. In the last ninety days, insiders sold 43,524 shares of company stock worth $24,871,960. 2.11% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have commented on IDXX. The Goldman Sachs Group increased their price target on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. Barclays boosted their price target on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Piper Sandler cut IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective on the stock. in a research note on Tuesday, January 30th. Finally, JPMorgan Chase & Co. boosted their target price on IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $591.50.

IDEXX Laboratories Stock Down 0.1 %

Shares of NASDAQ:IDXX opened at $477.79 on Friday. The stock’s 50-day moving average is $539.94 and its 200 day moving average is $508.49. The company has a market cap of $39.68 billion, a PE ratio of 47.45, a P/E/G ratio of 3.68 and a beta of 1.26. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.57 and a quick ratio of 1.17. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.12 by $0.20. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The firm had revenue of $901.60 million for the quarter, compared to analysts’ expectations of $891.88 million. During the same period in the previous year, the firm earned $2.05 earnings per share. The business’s revenue was up 8.8% compared to the same quarter last year. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.15 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.